May Cancer Diagnostic Probe reduce re-operation rate in post-neoadjuvant breast cancer patients undergoing breast conserving surgery? A 5-year retrospective study
This five-year retrospective study of 201 post-neoadjuvant breast cancer patients demonstrates that the Cancer Diagnostic Probe (CDP®) is a superior intraoperative tool for assessing tumor margins, achieving a high negative predictive value of 97.8% and a low reoperation rate of 1.49% compared to standard methods.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
When a woman is diagnosed with early-stage breast cancer, doctors often recommend a surgery that removes the tumor while leaving the rest of the breast intact. This approach, known as breast-conserving surgery, is a standard of care that preserves the body's shape and function. However, the success of this procedure hinges on a single, critical detail: the surgeon must remove the cancer completely, leaving a clean border of healthy tissue around the tumor. If even a tiny amount of cancer remains at the edge of the removed tissue, the patient faces the difficult prospect of returning to the operating room for a second surgery to clear those remaining cells.
This challenge becomes significantly harder when the patient has received chemotherapy before the operation. These drugs, given to shrink the tumor, can sometimes cause the cancer to disappear in some areas while leaving behind scattered, invisible islands of cells in others. The tissue itself can also become scarred and distorted, making it difficult for surgeons to see where the cancer ends and healthy tissue begins. The traditional method for checking the edges of the removed tissue during surgery involves freezing a small sample and examining it under a microscope. While useful, this technique is not perfect, especially after chemotherapy, and can sometimes miss remaining cancer cells, leading to the need for a second operation. Finding a way to check the edges more accurately in real-time is a major goal for improving patient care.
In a five-year study conducted at a medical center in Tehran, researchers tested a new tool designed to solve this specific problem. The device, called the Cancer Diagnostic Probe, works by sensing a biological signal that is common in cancer cells but rare in healthy ones. Cancer cells often struggle to get enough oxygen, a condition known as hypoxia. To survive, these cells change how they produce energy, creating a specific type of chemical byproduct. The probe is a small, handheld instrument that the surgeon can touch directly to the empty space left behind after the tumor is removed. It detects these chemical byproducts, which act as a warning sign that cancer cells might still be hiding in the tissue. If the probe signals a positive result, the surgeon can immediately shave away more tissue from that specific spot until the signal disappears, ensuring a cleaner margin before the patient leaves the operating room.
The researchers looked back at the records of 201 women who had undergone breast-conserving surgery after receiving chemotherapy between March 2020 and March 2025. All of these patients had their surgical margins checked using the Cancer Diagnostic Probe during the operation. The team then compared the probe's findings with the final, definitive laboratory analysis of the tissue, which is the gold standard for diagnosis. The results showed that the probe was highly effective at identifying when the margins were clear. Out of the 201 patients, only three were found to have cancer cells left at the edges despite the probe giving a negative signal. This means that for nearly every patient, the probe correctly confirmed that the surgery was complete, resulting in a very low rate of patients needing a second operation.
The study calculated that the tool correctly identified clear margins in 97.8 percent of cases. This high level of accuracy translated into a re-operation rate of just 1.49 percent. In contrast, other methods used in similar situations often lead to much higher rates of patients returning for additional surgery. The researchers noted that while the probe is excellent at confirming that a margin is clear, it is less precise at identifying exactly where cancer is present, sometimes flagging areas that look suspicious but turn out to be healthy. This happens because the probe detects the oxygen-starved environment that often surrounds a tumor, not just the cancer cells themselves. While this means the probe might suggest removing a bit more tissue than strictly necessary in some cases, the trade-off is a much lower chance of leaving cancer behind.
Beyond the clinical outcomes, the study highlighted the practical benefits of using this technology. Avoiding a second surgery saves the patient from the physical and emotional stress of another procedure and reduces the overall cost of care. The probe adds only a few minutes to the initial operation and costs a fraction of what a second surgery would require. The authors suggest that by using this tool to detect the hidden biological signs of cancer, surgeons can achieve a more thorough removal of the tumor in one go, particularly for patients who have already undergone chemotherapy. The findings support the idea that this new method offers a reliable way to navigate the complexities of post-chemotherapy surgery, helping to ensure that the first operation is the only one needed.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.